Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Daiichi Sankyo Co : Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/24/2012 | 07:59am CET

For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, General Manager, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan Tokyo, Japan (March 23, 2012) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will develop hydromorphone hydrochloride, a narcotic analgesic that has yet to be approved in Japan.

Hydromorphone hydrochloride is an opiate, narcotic analgesic that has been available outside of Japan for over 80 years. Although it is the standard for pain management for cancer pain treatment according to WHO guidelines, hydromorphone hydrochloride has yet to be approved in Japan.
Mundipharma K.K. had been requested by the Study Group on Unapproved and Off-label Drugs of High Medical Need* to develop hydromorphone hydrochloride in Japan, but after subsequent discussions it was decided that Daiichi Sankyo would develop the drug instead. The development of hydromorphone hydrochloride will contribute to the improvement of pain management options in Japan, and Daiichi Sankyo, through its commitment to corporate social responsibility, will continue to work to make unapproved and off-label drugs available in Japan in order to further contribute to medical treatment options for patients.
*A study group set up by Japan's Ministry of Health, Labour and Welfare to promote development by pharmaceutical companies of unapproved and off-label drugs in Japan that have been approved in the United States and Europe.
###

distributed by

This press release was issued by Daiichi Sankyo Co. Ltd. and was initially posted at http://www.daiichisankyo.com/news/20120321_376_E2.pdf . It was distributed, unedited and unaltered, by noodls on 2012-03-24 07:53:56 AM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
12/02 DAIICHI SANKYO : U.S. FDA Grants Fast Track Designation for HER2-Targeting Antib..
11/30 DAIICHI SANKYO : Announces Japanese Research Partners Selected for 2016 TaNeDS C..
11/21 DAIICHI SANKYO WEBCAST PRESENTATION : dbVIC - Deutsche Bank ADR Virtual Investo..
11/21 SUN PHARMACEUTICAL INDUSTRIES : Bright prospects
11/11 DAIICHI SANKYO : to present at the dbVIC - Deutsche Bank ADR Virtual Investor Co..
11/10 PIERIS PHARMACEUTICALS, INC. (NASDAQ : PIRS) Files An 8-K Reports Financial Resu..
11/10 International companies to host live webcasts at Deutsche Bank's Depositary R..
11/03 DAIICHI SANKYO : Mylan Launches First Generics of Benicar® and Benicar HCT® Tabl..
11/03 DAIICHI SANKYO : Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 T..
11/03 DAIICHI SANKYO : Ajanta pharma's bp drug in us
More news
Sector news : Pharmaceuticals - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11/07 FDA OKs Teva's generic version of blood pressure med Tribenzor
11/03 6 Ways To Profit From This Looming Disaster
10/22 ArQule Is Undervalued Going Into Catalyst Events
10/11 Daiichi Sankyo's late-stage study of leukemia candidate quizartinib underway
10/05 Free-For-All For Twitter
Advertisement
Financials ( JPY)
Sales 2017 924 537 M
EBIT 2017 -
Net income 2017 69 932 M
Finance 2017 298 375 M
Yield 2017 2,90%
P/E ratio 2017 22,93
P/E ratio 2018 24,01
EV / Sales 2017 1,53x
EV / Sales 2018 1,58x
Capitalization 1 710 135 M
More Financials
Chart DAIICHI SANKYO COMPANY, LI
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Full-screen chart
Technical analysis trends DAIICHI SANKYO CO...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 2 400  JPY
Spread / Average Target -0,50%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura Vice President-Finance & Accounting Department
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY..-3.25%15 061
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.85%168 544
More Results